🚀 VC round data is live in beta, check it out!
Cuorips Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cuorips and similar public comparables like Surrozen, CHO Pharma, Probi, DiaMedica and more.
Cuorips Overview
About Cuorips
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.
Founded
2017
HQ
Employees
59
Website
Sectors
Financials (FY)
EV
$340M
Cuorips Financials
Cuorips reported last fiscal year revenue of $1M and negative EBITDA of ($3M).
In the same fiscal year, Cuorips generated $1M in gross profit, ($3M) in EBITDA losses, and had net loss of ($4M).
Revenue (LTM)
Cuorips P&L
In the most recent fiscal year, Cuorips reported revenue of $1M and EBITDA of ($3M).
Cuorips expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 88% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (269%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (309%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (337%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cuorips Stock Performance
Cuorips has current market cap of $365M, and enterprise value of $340M.
Market Cap Evolution
Cuorips' stock price is $44.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $340M | $365M | -1.2% | XXX | XXX | XXX | $-0.49 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCuorips Valuation Multiples
Cuorips trades at 283.0x EV/Revenue multiple, and (105.2x) EV/EBITDA.
EV / Revenue (LTM)
Cuorips Financial Valuation Multiples
As of April 19, 2026, Cuorips has market cap of $365M and EV of $340M.
Equity research analysts estimate Cuorips' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cuorips has a P/E ratio of (90.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $365M | XXX | $365M | XXX | XXX | XXX |
| EV (current) | $340M | XXX | $340M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 283.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (105.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (91.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 321.3x | XXX | XXX | XXX |
| P/E | — | XXX | (90.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (59.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cuorips Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cuorips Margins & Growth Rates
Cuorips' revenue in the last fiscal year grew by 28%.
Cuorips' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Cuorips Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 28% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (269%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (0%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 397% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cuorips Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cuorips | XXX | XXX | XXX | XXX | XXX | XXX |
| Surrozen | XXX | XXX | XXX | XXX | XXX | XXX |
| CHO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Probi | XXX | XXX | XXX | XXX | XXX | XXX |
| DiaMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Immuneering | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cuorips M&A Activity
Cuorips acquired XXX companies to date.
Last acquisition by Cuorips was on XXXXXXXX, XXXXX. Cuorips acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cuorips
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCuorips Investment Activity
Cuorips invested in XXX companies to date.
Cuorips made its latest investment on XXXXXXXX, XXXXX. Cuorips invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cuorips
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cuorips
| When was Cuorips founded? | Cuorips was founded in 2017. |
| Where is Cuorips headquartered? | Cuorips is headquartered in Japan. |
| How many employees does Cuorips have? | As of today, Cuorips has over 59 employees. |
| Who is the CEO of Cuorips? | Cuorips' CEO is Takayuki Kusanagi. |
| Is Cuorips publicly listed? | Yes, Cuorips is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Cuorips? | Cuorips trades under 4894 ticker. |
| When did Cuorips go public? | Cuorips went public in 2023. |
| Who are competitors of Cuorips? | Cuorips main competitors are Surrozen, CHO Pharma, Probi, DiaMedica. |
| What is the current market cap of Cuorips? | Cuorips' current market cap is $365M. |
| What is the current revenue of Cuorips? | Cuorips' last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of Cuorips? | Current revenue multiple of Cuorips is 283.0x. |
| Is Cuorips profitable? | No, Cuorips is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.